Migraine

This health economic analysis predicted that, compared with use of supportive care, erenumab treatment will reduce the direct and indirect costs associated with migraine and increase quality-adjusted life-years for patients who have previously experienced treatment failure with at least 1 preventive migraine treatment.

Employers that offer healthcare benefits, paid sick days, and disability insurance benefits will spend about $84,000 in annual migraine-related costs for every 1000 employees.

Despite behavioral migraine treatment being effective, safe, and well-tolerated, less than one-third of eligible patients are referred for treatment and only half of those referred initiate treatment.

While the pilot study successfully explored the efficacy of timolol eyedrops, further research is necessary to identify patients who would benefit the most from this treatment and an appropriate dosage.

The large-scale patient registry and biorepository includes patient information and biological samples and leverages machine learning to track the progress of patients over time.

Galcanezumab demonstrated clinically and statistically significant benefits across several migraine-relevant outcomes when compared to placebo.

Erenumab is the first calcitonin gene-related peptide (CGRP) inhibitor to be approved by the FDA for the prevention of migraine. The Institute for Clinical and Economic Review assessed the comparative effectiveness and value of erenumab with 2 other CGRP inhibitors that are still under FDA review.

Two studies presented at the International Society of Pharmacoeconomic and Outcomes Research Annual International Meeting investigated the economic and clinical burdens on patients diagnosed with migraine.

Working age migraineurs are more likely to experience painful musculoskeletal disorders, such as fibromyalgia and depression, than those without migraine.

Two study abstracts presented at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, in Baltimore, Maryland, examined the prevalence of preventive and opioid treatment for migraine.

Neck pain associated with migraine cannot be attributed to increased trapezius activity during rest, mental stress, and physical activity or prolonged muscle activity and should be seen as an accompanying symptom of migraine.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The FDA has approved Amgen and Novartis’ erenumab-aooe, marking the first approved calcitonin gene-related peptide (CGRP) inhibitor for the prevention of migraine in adults. The treatment will cost 30% less than expected.

Chronic migraine is associated with pain, psychiatric, and endocrine/neurological comorbidities, as well as sleep disorders.

The Institute for Patient Access has issued a response to the Institute for Clinical and Economic Review (ICER) following its report assessing the clinical effectiveness and economic value of calcitonin gene-related peptide (CGRP) inhibitors for the treatment of chronic or episodic migraines.

Common polygenic variation significantly contributes to the aggregation of migraine in families, whether they are common or rare subtypes.

Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts, discusses specialty drugs that have recently been approved, and which we will likely see approved in the remainder of the year.

Combined, migraine-related absenteeism and presenteeism is responsible for 86 million lost workdays and costs £8.8 billion annually.

Women with a past history of migraine have a 15% higher risk of developing hypertension than those with no history of migraine, according to study findings published in Cephalalgia.

After 3 months of treatment with a single-pulse transcranial magnetic stimulation, patients averaged 3 fewer migraines per month, according to study findings.

Migraine is a chronic illness, but many people, including both patients and healthcare providers­, don’t think of it that way, said Richard G. Wenzel, PharmD, CPPS, speaking at the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting held April 23-26, in Boston, Massachusetts.

Women account for over 75% of Americans who experience migraines, which could be attributable to the way that estrogen levels affect cells in the brain, according to new study findings.

Amgen and Novartis announced full results from the LIBERTY trial, which assessed erenumab as preventive treatment for patients with episodic migraine who had previously failed on 2 to 4 treatments. The study met its primary endpoint and all of its secondary endpoints.

While calcitonin gene-related peptide (CGRP) inhibitors are projected to have a positive impact on the health of patients with chronic or episodic migraines for whom preventive therapy had failed relative to no treatment, it is likely that the inhibitors will exceed commonly-cited willingness-to-pay thresholds, according to a report from the Institute for Clinical and Economic Review (ICER).

The pharmaceutical company announced that rimegepant, for the acute treatment of migraines, demonstrated superiority to placebo and met the co-primary endpoints of pain freedom and freedom from the most bothersome symptom in 2 pivotal phase 3 trials.

Novartis' calcitonin gene-related peptide (CGRP) inhibitor for prevention of migraine, erenumab, showed positive results in a phase 3b study in episodic migraine patients who have failed multiple prior preventive treatments.